Five Prime(FPRX)

牛唐2021-04-13 21:53

$再鼎医药(ZLAB)$ 选药眼光真毒，$Five Prime(FPRX)$ 被收购，$Novocure(NVCR)$ 数据不错查看全文

7X24快讯2021-03-05 14:44

【安进19亿美元收购Five Prime Therapeutics】3月4日，安进(AMGN.O)宣布与Five Prime Therapeutics(FPRX.O)达成最终协议，将以38美元/股的价格全现金收购后者股票，对应股权总金额大约19亿美元。安进通过此次收购补强了自己的肿瘤创新药管线，包括获得了first in class的FGFR2b单抗bemarituzumab，...查看全文

牛唐2021-03-05 14:16

医药板块观察（2021.03.04）
1、$Five Prime(FPRX)$\$Pandion Therapeutics(PAND)相继被并购，可否燃起医药板块的热情？
2、$Talis Biomedical(TLIS)$ 新股破发，是否有配置价值？
$快手-W(01024)$查看全文

小小糖果2021-03-05 03:31

$Five Prime(FPRX)$ 今天唯一的安慰。查看全文

lisaff2021-03-05 01:15

$Five Prime(FPRX)$ 这么平的走势，怎么做到的呢查看全文

chuminhua2021-03-04 23:29

3月4日，安进（Amgen）宣布将以19亿美元收购Five Prime。Five Prime的核心产品为FGFR2b抗体bemarituzumab等。再鼎医药于2017年以500万美元预付款+3900万美元里程碑金额引进Bemarituzumab的大中华区权益。$安进(AMGN)$ $Five Prime(FPRX)$查看全文

产业链观察2021-03-04 22:35

药闻| 2021年3月4日，- $安进(AMGN)$ 和$Five Prime(FPRX)$ (一家临床阶段的生物技术公司，专注于开发免疫肿瘤以及针对性癌症疗法)，今天宣布了一项协议，安进公司将以每股38.00美元的现金价格收购Five Prime Therapeutics ，相当于约19亿美元的股权价值。
此次收购将Five Prime的创新产品线添...查看全文

Replix锐璞美股2021-03-04 22:03

$Five Prime(FPRX)$ 被收购！
Amgen (NASDAQ: AMGN) and Five Prime Therapeutics (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies, today announced an agreement under which Amgen will acquire Five Prime ...查看全文

牛唐2020-12-08 22:00

$居里(CRIS)$ 继$Five Prime(FPRX)$ 之后，第二个爆发的BVF概念股，下一个是谁？$蔚来(NIO)$查看全文

chuminhua2020-11-12 22:14

Five Prime Therapeutics日前宣布，其“first-in-class”靶向FGFR2b的单克隆抗体疗法bemarituzumab（FPA144），与化疗联用，在一线治疗晚期胃癌或胃食管连接部（GEJ）癌患者的2期临床试验中获得积极结果。这些患者的肿瘤为FGFR2b阳性，HER2阴性。新闻稿指出，这是首个表明针对FGFR2b的靶向治疗可能...查看全文

$FIVE PRIME THERAPEUTICS INC(FPRX)$ 8-K - Current report Filed: 2015-09-10 AccNo: 0001193125-15-316993 Size: 32 KBItem 8.01: Other EventsItem 9.01: Financial Statements and Exhibits 网页链接

$FIVE PRIME THERAPEUTICS INC(FPRX)$ 8-K - Current report Filed: 2015-05-13 AccNo: 0001193125-15-185933 Size: 51 KBItem 2.02: Results of Operations and Financial ConditionItem 9.01: Financial Statements and Exhibits 网页链接

$FIVE PRIME THERAPEUTICS INC(FPRX)$ 8-K - Current report Filed: 2015-08-21 AccNo: 0001193125-15-299082 Size: 19 KBItem 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers http:...

$FIVE PRIME THERAPEUTICS INC(FPRX)$ 10-Q - Quarterly report [Sections 13 or 15(d)] Filed: 2015-08-07 AccNo: 0001564590-15-006573 Size: 4 MB 网页链接

$FIVE PRIME THERAPEUTICS INC(FPRX)$ 8-K - Current report Filed: 2015-08-06 AccNo: 0001193125-15-281100 Size: 58 KBItem 2.02: Results of Operations and Financial ConditionItem 9.01: Financial Statements and Exhibits 网页链接

$FIVE PRIME THERAPEUTICS INC(FPRX)$ 8-K - Current report Filed: 2015-07-15 AccNo: 0001193125-15-253650 Size: 47 KBItem 1.01: Entry into a Material Definitive AgreementItem 9.01: Financial Statements and Exhibits 网页链接

$FIVE PRIME THERAPEUTICS INC(FPRX)$ 8-K - Current report Filed: 2015-06-15 AccNo: 0001193125-15-223322 Size: 17 KBItem 5.07: Submission of Matters to a Vote of Security Holders 网页链接

$FIVE PRIME THERAPEUTICS INC(FPRX)$ 8-K - Current report Filed: 2015-05-13 AccNo: 0001193125-15-185933 Size: 51 KBItem 2.02: Results of Operations and Financial ConditionItem 9.01: Financial Statements and Exhibits 网页链接

$FIVE PRIME THERAPEUTICS INC(FPRX)$ 10-Q - Quarterly report [Sections 13 or 15(d)] Filed: 2015-08-07 AccNo: 0001564590-15-006573 Size: 4 MB 网页链接

$FIVE PRIME THERAPEUTICS INC(FPRX)$ 10-Q - Quarterly report [Sections 13 or 15(d)] Filed: 2015-05-14 AccNo: 0001564590-15-004229 Size: 4 MB 网页链接